drugset / Trial / NCT02873650
Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.
Timeline
- Start
- 2016-12-20
- Primary completion
- 2018-10-12
- Completion
- 2019-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 100 mg | Oral |
Indications
No indication recorded.